SCHEMBL2033790

SCHEMBL2033790

COCCOP(=O)(Cc1ccc([N+](=O)[O-])cc1)OCCOC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.50
ALDH1A1 P00352 4/20 0.46
HSD17B10 Q99714 3/20 0.46
CYP3A4 P08684 2/20 0.46
MAPK1 P28482 2/20 0.46
LMNA P02545 2/20 0.46
TP53 P04637 1/20 0.46
THRB P10828 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
ACHE P22303 2/20 0.44
BCHE P06276 1/20 0.44
IDO1 P14902 2/20 0.44
TSHR P16473 2/20 0.43
LOXL2 Q9Y4K0 1/20 0.43
CYP2C19 P33261 2/20 0.41
CYP1A2 P05177 1/20 0.41
POLB P06746 2/20 0.40
KCNH2 Q12809 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL78561 0.84 CA1 (0.58) AKR1C3ALDH1A1HSD17B10CYP3A4MAPK1
SCHEMBL11225497 0.83 ALDH1A1 (0.51) AKR1C3ALDH1A1HSD17B10CYP3A4MAPK1
SCHEMBL2029331 0.77 ALDH1A1 (0.42) ALDH1A1CYP3A4LMNASMN1; SMN2CYP2C19
SCHEMBL13537855 0.77 AKR1C3 (0.60) AKR1C3ALDH1A1LMNASMN1; SMN2IDO1
SCHEMBL3434694 0.77 AKR1C3 (0.49) AKR1C3ALDH1A1HSD17B10CYP3A4MAPK1
SCHEMBL27867485 0.77 AKR1C3 (0.51) AKR1C3ALDH1A1LMNASMN1; SMN2CA1
SCHEMBL2035155 0.77 CA2 (0.43) ALDH1A1CYP3A4MAPK1CA1CA2
SCHEMBL4985770 0.76 TSHR (0.58) AKR1C3ALDH1A1HSD17B10CYP3A4MAPK1
SCHEMBL5770723 0.76 AKR1C3 (0.47) AKR1C3ALDH1A1HSD17B10CYP3A4MAPK1
SCHEMBL2031961 0.76 CA1 (0.56) AKR1C3ALDH1A1HSD17B10CYP3A4MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096624-B2 Amino pyrimidine anticancer compounds OSI Pharmaceuticals, LLC (US) 2015-08-04 US disclosed
US-20130231306-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI Pharmaceuticals, LLC (US) 2013-09-05 US disclosed
US-8399433-B2 Amino pyrimidine anticancer compounds OSI Pharmaceuticals, LLC (US) 2013-03-19 US disclosed
EP-2438056-A2 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI Pharmaceuticals, LLC (US) 2012-04-11 EP disclosed
US-20110136764-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2011-06-09 US disclosed
WO-2010141406-A2 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130231306-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS DPYD, PTK2, TYMS AKR1C3 4372/4885ALDH1A1 1117/4885HSD17B10 4560/4885
US-20110136764-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS DPYD, PTK2, TYMS AKR1C3 4372/4885ALDH1A1 1117/4885HSD17B10 4560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.